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In drug discovery, chemical screening is performed after
a protein’s function has been determined. By screening
for ligands that alter the function of a cell or an
organism, new proteins that participate in poorly
understood biological processes can be identified.
Genomic and expression-cloning technologies can
rapidly identify the protein targets of these ligands,
enhancing the power of chemical screening as a tool for
the initial stages of biological discovery.
Address: Institute of Chemistry and Cell Biology and Department of
Cell Biology, Harvard Medical School, 250 Longwood Avenue,
SGM 604, Boston, MA 02115, USA.
E-mail: randy_king@hms.harvard.edu
Chemistry & Biology December 1999, 6:R327–R333
1074-5521/99/$ – see front matter 
© 1999 Elsevier Science Ltd. All rights reserved.
In 1775 a man with a weak heart improved after obtaining
an herbal extract from a gypsy; two centuries later we con-
tinue to use digoxin as a treatment for congestive heart
failure. In 1928, a spore wafted into a petri dish in a
London laboratory, a fungus grew, and neighboring bacte-
ria were killed. The subsequent isolation and production
of penicillin led to a new era in the treatment of infectious
disease. In the 1970s, fungal extracts were screened for
the ability to inhibit antibody production in mice. Today
organ transplantation has become a routine procedure
thanks to the availability of potent immunosuppressants
such as cyclosporin A and FK506. 
These examples illustrate that powerful drugs can be dis-
covered even when little is known about the underlying
biology. Prior to the advent of modern genetics, pharma-
cologic agents such as natural products and synthetic com-
pounds were the primary tools available for perturbing
biological systems. Even with the explosive growth of
molecular biology, natural products continue to provide
clues to unravel the molecular details of the biological
systems in which they were discovered. For example, the
identification of histone deacetylase as the target of the
natural product trapoxin stimulated a broad examination
of the role of protein acetylation in the regulation of tran-
scription [1]. Despite the enormous potential of small mol-
ecules to open new areas of biological investigation, most
screening efforts today search for activators or inhibitors of
known proteins. In the paradigm that is coming to domi-
nate pharmaceutical discovery, biological and genomic
approaches are used to discover and validate biological
targets [2]; a chemical screen is then performed against the
isolated target protein. Although this approach may be
appropriate when the primary goal is to develop therapeu-
tic agents, it lacks the power to discover new proteins and
new biological principles. By performing chemical screens
in intact cells, tissues and organisms, and then using
genomics, molecular biology and biochemistry to identify
the biological target, it may be possible to discover many
new ligands that could be used to dissect complex biologi-
cal systems at the molecular level. 
This open-ended approach to small-molecule screening is
analogous to the hunt for mutants conducted during a
genetic screen, and has therefore been referred to as
‘chemical genetics’ [3–5]. In both cases the function of a
specific protein is altered, either by ligand binding or
through mutation of the DNA that encodes the protein.
To assign function at the molecular level, the binding
protein or the mutated gene must be identified. Modern
genetic techniques have made the process of identifying
mutant genes straightforward in many model organisms.
In contrast, one of the limitations of chemical genetics is
that target identification is often difficult and can become
rate-limiting. Fortunately, several new approaches, fueled
by the revolution in genomics, have been developed to
speed the process of target identification. Ironically,
although genomics will undoubtedly continue to identify
candidate genes for drug screening, genomics and expres-
sion cloning have the potential to accelerate target identi-
fication to the point that chemical screening could become
the first step in the process of biological discovery, rather
than always being performed at its conclusion. 
Guilt by association: genomic strategies for target
identification
In a chemical-genetic screen, small molecules are
screened for their ability to alter some aspect of cellular
function. The physiological consequences of treatment
with the active compound often extend beyond the phe-
notype monitored in the screen, however. These alter-
ations in cell physiology can often highlight the biological
pathway perturbed by the compound, even if they are not
sufficiently informative to identify the molecular target.
Although many aspects of cell physiology could be moni-
tored, the genome-wide analysis of the effect of a small
molecule on transcription is perhaps the most general
approach and provides a rich source of information [6].
The basic experiment is to determine which transcripts
increase or decrease in abundance after cells are treated
with a small molecule. Generally this is carried out by
obtaining samples of mRNA from treated and untreated
cells, labeling the samples with fluorescent tags, and
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hybridizing the products to an array of cDNAs [7] or
oligonucleotides [8]. Because most DNA microarrays
contain genes of both known and unknown function, the
information can be used in two different ways. By moni-
toring the expression of known genes, it may be possible
to determine the metabolic or regulatory pathways that are
affected by the small molecule. For example, the cyclin-
dependent kinase inhibitor purvalanol inhibits the expres-
sion of genes that encode B-type cyclins [9]; earlier
genetic work had demonstrated that kinase activity is
required for expression of these genes. Changes in the
expression levels of unknown genes are also informative
as they generate a fingerprint that can be used to compare
the effects of one small molecule with those of another.
By developing a database of these profiles, it may become
possible to classify compounds by mechanism on the basis
of similarities in the induced transcriptional changes.
Recently, the power of transcriptional profiling has been
coupled with yeast genetics to identify targets and assess
the specificity of natural products and synthetic molecules
(Figure 1). To identify or confirm a particular gene
product as the biological target of a small molecule, a yeast
strain is constructed that contains either a deletion or con-
ditional mutation in the putative target gene. The tran-
script profile of yeast treated with a small molecule is then
compared with the profile of the mutant strain. For
example, the transcript profile of yeast treated with FK506
was found to be very similar to the pattern produced by
deletion of the calcineurin gene, confirming earlier studies
that calcineurin is a target of FK506 in yeast [10]. Efforts
are currently underway to systematically delete every
yeast gene [11]. Once a transcript profile is obtained from
each strain, this set of profiles could be searched using the
pattern produced by treatment with a small molecule to
identify candidate target genes. 
A clever variation of the profiling approach allows the func-
tional specificity of a small molecule to be assessed [10].
Instead of using a wild-type strain for the analysis, the puta-
tive target gene is deleted, and the mutant strain is treated
with the ligand. If the transcript pattern in the mutant strain
does not change upon treatment with the small molecule, it
suggests that the deleted gene is the primary target of the
ligand. If the levels of transcripts change, however, the
approach indicates that there may be additional proteins
affected by the small molecule. When a strain carrying a
deletion of the calcineurin gene was treated with FK506, it
was found that several transcripts changed in abundance,
suggesting that there may be additional targets of FK506 in
budding yeast [10]. This is an especially exciting technique,
as there are few general methods for assessing the speci-
ficity of action of small molecules. 
A second promising strategy for target identification also
combines genome-scale technologies with yeast genetics
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Figure 1
Confirming the biological target of a small molecule using expression
profiling and genetics. mRNA is isolated from wild-type and mutant
yeast strains in the presence and absence of the test ligand. The mRNA
is converted to fluorescently labeled cDNA, and two samples are
hybridized against one another in a competitive fashion to a DNA
microarray. The array is imaged to quantitate the abundance of each
labeled species. If the first sample produces a higher signal, the spot is
red; if the second sample produces a higher signal, the spot is green; if
the signals are equal, no color is shown. In the first experiment, the
effects of treating a wild-type strain with the ligand are determined by
hybridizing samples obtained before and after treatment with a small
molecule (A versus B). Next, samples are obtained from the wild-type
and mutant strains in the absence of ligand, and hybridized against one
another (A versus C). If the deleted gene is the target of the small
molecule, the profile from the first experiment should look similar to that
from the second experiment. If the deleted gene is not the target, then
the profiles from the two experiments may look substantially different. To
confirm that the deleted gene is indeed the target of the small molecule,
the mutant strain is treated with ligand (C versus D). If the true target
has been deleted, treatment of the mutant strain should produce no
changes in transcript levels, producing a blank picture. If the deleted
gene is not the target, however, then the pattern of changes may
resemble that produced by treating the wild-type strain. 
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[12]. The approach takes advantage of the fact that a
single copy of a gene, even if it is essential, is generally
sufficient to support normal growth of a diploid yeast
strain [11]. However, because a strain containing a single
copy of a particular gene typically expresses less of the
encoded protein, the strain may become hypersensitive to
a small molecule that inhibits the product of the haploid
locus. Candidate target genes can therefore be identified
by systematically testing a panel of deletion strains for
hypersensitivity to a compound. Although each strain
could be tested individually, genomic techniques make it
possible to perform the analysis in a single experiment. By
inserting within each strain a unique DNA sequence that
can be amplified using the polymerase chain reaction
(PCR), the abundance of each strain within a mixture can
be quantified by hybridization of the PCR products to an
oligonucleotide array. Therefore, many strains can be
pooled together and grown competitively in the presence
of the ligand. Hypersensitive strains will grow the slowest,
and will produce the weakest signal when the molecular
tags are analyzed. This technique has demonstrated that
the ALG7 gene, encoding a glycosyltransferase, can be
identified as the target of tunicamycin when a panel of 233
deletion strains was analyzed in a single experiment [12]. 
These approaches illustrate the power of combining
genomic technologies with genetics to aid in the process
of target identification. A major advantage compared with
the affinity methods described below is that the ligand
does not need to be chemically modified, allowing many
small molecules to be tested rapidly. Although transcrip-
tional profiling can now be performed in several experi-
mental systems, the major limitation of the two
techniques described above is that they can only be per-
formed in organisms in which proteins can be genetically
inactivated. Currently, this includes microorganisms such
as bacteria and yeast, and metazoans such as the fruit fly,
the nematode and the mouse. 
Caught in the act: target identification by expression
cloning
Because most natural products exert their cellular effects
by binding to specific proteins, biochemical affinity
methods have traditionally been the major approach used
for target identification. Examples include affinity chro-
matography, in which a protein is purified based on its
binding to the natural product, and affinity labeling, in
which a labeled version of the ligand becomes covalently
attached to the target protein, facilitating its purification.
In each case the ligand must first be chemically modified
to facilitate attachment to a solid-phase matrix, cross-
linking agent or biochemical label. Cellular lysates are then
incubated with the derivatized compound, and the puta-
tive target proteins purified by virtue of their binding to
the small molecule. To isolate the gene encoding the
binding protein, the protein must be microsequenced, and
the sequence information used to identify the correspond-
ing clone from a cDNA library. Although gene sequence
databases make it possible to identify the gene without
actually isolating the clone, the process of biochemical
purification and peptide sequencing remain time consum-
ing. Biochemical purification approaches can also fail if the
protein is present at low levels, is unstable, or additional
nonspecific proteins bind to the affinity resin. 
Over 15 years ago, a method called expression cloning was
developed to identify genes encoding proteins of interest,
without requiring that the protein first be purified and
microsequenced. The essence of the method is to express
proteins from a cDNA library, and then to screen or select
for cells expressing the activity of interest. The approach
was first used to identify subunits of yeast RNA poly-
merase II by expressing a yeast cDNA library in an
Escherichia coli bacteriophage, and using an antibody
against the polymerase to identify colonies expressing the
desired protein [13]. Many variations of this approach have
been developed subsequently. Proteins can be expressed
in tissue culture cells, Xenopus oocytes, yeast and cell-free
lysates; the choice of expression system is generally deter-
mined by the nature of the screening method. Cell-based
expression-cloning methods have identified transmem-
brane receptors, secreted ligands and ion channels [14];
the yeast two-hybrid method has discovered interacting
proteins [15]; cell-free expression systems have identified
substrates for kinases, proteases and even enzymes them-
selves [16]. There are many different methods for identi-
fying the active cDNA from the large library of inactive
clones. In some cases, the library is spatially arrayed onto
petri plates or filters, and the active clone identified by its
location. When it is not possible to spatially array individ-
ual clones, the cDNA library can be grouped into pools of
clones, and each pool screened for activity. The active
pool is then divided into a series of smaller pools and the
process repeated until the active clone is identified. In
some forms of expression cloning, such as phage display,
the cDNA remains physically linked to the protein that it
encodes. This enables direct selection of the phage and its
associated cDNA from large libraries.
Despite the fact that expression cloning has been used for
a long time to identify proteins with specific biochemical
properties, the technique has only been applied to the
problem of natural-product target identification in the past
few years. Four different expression-cloning methods have
now been adapted to identify the protein targets of small
molecules. The first method described is derived from the
yeast two-hybrid system [17], which is typically used to
identify interacting proteins. In the standard method, two
different hybrid proteins are expressed in the same cell:
the first hybrid consists of a DNA-binding protein fused to
the ‘bait’ protein; the second hybrid is composed of a
cDNA library member fused to a transcriptional activator.
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If the bait protein binds to a library protein, the transcrip-
tional activator is brought in proximity with the DNA, and
a reporter protein is transcribed. To identify natural-
product targets, the bait protein is replaced by a protein
that binds a known ligand, such as the hormone-binding
domain of the gluococorticoid receptor. The natural
product is then modified by attachment of the cognate
ligand, such as dexamethasone (Figure 2a). If a library
protein is present that binds the modified natural product,
the protein will be recruited to the DNA and transcription
will be activated. This method, referred to as a ‘three-
hybrid’ technique, was used to demonstrate that a known
FK506-binding protein (FKBP12) could be identified
from a human cDNA library (Figure 3a) [17] when an
FK506–dexamethasone hybrid ligand (Figure 2a) was
used. Other researchers have demonstrated that it is also
possible to perform three-hybrid screening in mammalian
tissue culture cells [18]. 
The receptor for the natural product capsaicin has also
been identified using a functional expression-cloning tech-
nique in tissue culture cells [19]. Capsaicin (Figure 2b), the
active component of hot peppers, was thought to bind to a
receptor in neurons that sense pain. Physiological studies
indicated that capsaicin treatment caused calcium to rush
into these neurons. On the basis of these observations, an
expression-cloning approach was developed to identify the
receptor (Figure 3b). A cDNA library was constructed from
the neurons that respond to capsaicin, divided into pools of
16,000 clones, and each pool was then transfected into
tissue-culture cells lacking the receptor. The cells were
then treated with capsaicin and examined by fluorescence
microscopy, using a dye that fluoresces when intracellular
calcium levels rise. One pool of clones gave a positive
signal, and this pool was subdivided into progressively
smaller samples until a single clone was identified that was
sufficient to support the capsaicin-induced calcium influx.
The active clone proved to be a transmembrane channel
that is directly activated by capsaicin. Interestingly, the iso-
lation of this receptor led to the subsequent discovery that
it also senses heat (explaining why we perceive capsaicin as
hot), again illustrating how a natural product provided a
crucial tool for understanding a basic biological process. 
A recent study used a bacterial expression-cloning tech-
nique called a ‘drug-western’ to identify several potential
targets of an experimental sulfonamide anticancer drug [20]
(Figures 2c,3c). A cDNA library was constructed in a lambda
bacteriophage, similar to the type used for the expression
cloning of RNA polymerase II. Each bacteriophage carries a
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Figure 2
Chemical structures of ligands used in
expression cloning methods.
(a) Dexamethasone–FK506 conjugate used
for three-hybrid cloning. (b) Capsaicin, the
ligand used for expression cloning in tissue
culture cells. (c) Bovine serum albumin (BSA)
conjugate of HMN-154, an experimental
anticancer agent, used in the drug-western
approach. (d) Biotin–FK506 conjugate used
in phage-display cloning. 
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different member of the cDNA library, which is expressed
when the virus infects the cell. Infection by virus leads to
lysis of the cells, causing a small clearing (called a plaque) in
the lawn of bacteria. Each plaque represents a unique virus
and therefore contains a single member of the library. Typi-
cally a single petri plate can contain thousands of plaques.
The proteins in the plaques are transferred to nitrocellu-
lose filters, where they can be probed with antibodies, or,
as in this modified approach, with a drug conjugated to
bovine serum albumin (BSA). An antibody that recognizes
BSA, coupled to horseradish peroxidase (HRP), can then
be used to identify plaques containing drug-binding pro-
teins. In the recently published study, two million
plaques were screened, and ten were found to bind the
drug–BSA conjugate. Six of the clones showed no homol-
ogy to known proteins, whereas the remaining four
encoded the transcription factor NF-YB, thymosin β-10,
growth hormone and gonadotropin-releasing hormone.
Although the latter clones probably represent nonspecific
binding proteins, the authors demonstrated that their
compound could inhibit the binding of NF-YB to its
cognate DNA sequence, suggesting that this target may
be physiologically relevant. 
The final approach, reported very recently, takes advan-
tage of phage display, which is also a prokaryotic expres-
sion cloning method [21] (Figure 3d). In contrast to the
drug-western technique, the cDNA library members are
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Figure 3
Expression-cloning methods used for target
identification. (a) The three-hybrid approach.
Each cell expresses two different hybrid
proteins, including a fusion of the DNA-binding
protein LexA to the glucocorticoid receptor
(GR), and a protein consisting of a cDNA
library member (LP, for library protein) fused to
a transcriptional activation domain (AD). In the
presence of ligand, consisting of a hybrid
dexamethasone-test ligand (TL) conjugate, the
transcriptional activator is brought in proximity
of the DNA, activating the expression of a
reporter protein. (b) Identification of the
capsaicin receptor using a functional approach
in tissue culture cells. Pools of cDNAs are
transfected into tissue culture cells. Pools
containing an active receptor (red) cause
transfected cells to allow calcium to enter cells
in the presence of capsaicin (blue cells), as
imaged using microscopy. Multiple rounds of
subdivision and screening are performed until
a single active clone is identified. (c) Drug-
western approach. A bacteriophage
expressing a cDNA library is used to infect
bacteria plated onto petri dishes. The
expressed proteins, found in each plaque, are
transferred to nitrocellulose filters, which are
incubated with a drug–BSA conjugate, and
detected with an anti-BSA antibody coupled to
horseradish peroxidase (HRP). The
corresponding plaque is isolated from the petri
dish, purified to isolate a single virus, and the
encoded protein is identified by sequencing
the DNA. (d) Display cloning. A cDNA library
is produced in the T7 bacteriophage, such that
each library member (colored spot) is fused to
the phage coat protein. The phage are passed
over a monomeric avidin column containing the
test ligand fused to biotin. Phage that bind to
the test ligand are then eluted by addition of
biotin to the column. The binding population
can then be reamplified by infection of a liquid
culture, and the resulting population selected
again on the affinity matrix. Purified phage are
then obtained, and the DNA sequenced to
identify the encoded binding proteins. 
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expressed as fusion proteins together with the viral coat
protein, such that each cDNA remains physically associ-
ated with the protein it encodes. Because the phage parti-
cles are soluble and can be produced by infection of a
liquid culture, large numbers of phage can be produced,
and selected phage can be rapidly amplified. Although
phage display has primarily been used for expression of
peptide libraries, several recent technical improvements
have allowed cDNA libraries to be successfully displayed
on the phage surface. In the recent application, FK506
was chemically coupled to biotin (Figure 2d), allowing
reversible attachment to a monomeric avidin resin. A
cDNA library derived from human brain was then
expressed by fusion to the coat protein of the T7 bacterio-
phage, and the phage particles passed over the affinity
matrix. Phage binding to the column by virtue of the
FK506 interaction were eluted from the monomeric avidin
matrix by addition of biotin. The eluted phage were then
used to reinfect a second culture, amplifying the eluted
population, and the affinity selection was repeated. After
two rounds of selection, FKBP12 was identified as the
sole binding activity. This technique illustrates that
natural-product targets can be identified very rapidly,
even when large numbers of clones are present in the
initial cDNA library. 
Although expression cloning can provide a rapid alternative
to traditional biochemistry for identifying natural-product
receptors, care must be taken when choosing the expression
system. For functional expression cloning, it is important
that the target protein not be highly expressed in the cell
type used for screening, as the endogenous protein may
interfere with detection of the desired activity. Expression
cloning may also fail if the protein is not expressed in the
proper cellular compartment; the target of capsaicin could
not have been identified using yeast or bacterial expression-
cloning methods. Certain cytosolic targets may be difficult
to identify using prokaryotic expression systems because
many eukaryotic proteins do not fold properly when
expressed in E. coli. Approaches such as phage display or
the yeast three-hybrid system, which require that library
proteins be expressed as a fusion proteins, may also render
the library proteins incapable of binding the natural
product. A significant limitation of most expression-cloning
approaches is that proteins are screened one at a time; if the
products of more than one cDNA are required for binding,
it is unlikely to be identified. An excellent example is
FK506 itself: although FK506 indeed binds to FKBP12,
this protein alone is not the biological target. A complex of
FK506 bound to FKBP12 inhibits the phosphatase calci-
neurin, which is the physiological target of inhibition [22]. 
Integrating genomic resources with expression cloning to
accelerate target identification
The availability of fully sequenced genomes promises to
speed expression cloning by providing a uniform set of
genes from which proteins can be expressed, and by
allowing new methods of analysis to be employed in
screens. Current cDNA libraries are made by reverse tran-
scription of cellular mRNA. If a particular mRNA is abun-
dant, it will be present at a high frequency in the library
and will therefore be easy to identify, whereas if it is
expressed poorly, it will be present at low frequency and
more clones will have to be screened. Although normal-
ization procedures can increase the relative representation
of rare messages, the procedures are not perfect. Another
limitation of current cDNA libraries is that many clones
do not encode full-length proteins, as library members
may be derived from partially degraded mRNA. With the
availability of fully sequenced genomes, it should be pos-
sible to create the perfect library in which every clone
encodes a full-length protein and is represented once.
The entire set of such clones from an organism is referred
to as a ‘unigene’ set. 
The availability of unigene libraries may also provide new
tools for analyzing the results of expression-cloning exper-
iments. Currently, each active clone must be individually
isolated and sequenced to identify it. Expression-cloning
methods such as phage display that couple the DNA
sequence directly to the expressed protein may enable
genomic tools to be used for analysis, however. Certain
cell-free expression systems also allow genetic informa-
tion, in the form of mRNA, to remain coupled to the
expressed protein [23]. Because the genetic information is
retained with the protein when an affinity selection is per-
formed, it may be possible to rapidly identify all of the
proteins that bind to an affinity resin. For example, library
proteins could be fluorescently labeled, passed over the
affinity column, and specific binding proteins identified
by hybridization of the associated cDNA or mRNA to a
DNA microarray. The same unigene cDNA library would
be used twice: first to direct the synthesis of each library
protein, and second to create the microarray of cDNAs
required for the analysis. This approach would enable all
binding proteins to be identified rapidly in a single experi-
ment, providing information regarding specificity in addi-
tion to identifying the primary target.  
Until recently, a limited number of approaches have been
available for identifying the biological targets of small
molecules. It is therefore understandable that most chemi-
cal screens use single defined proteins, eliminating the
need for target identification. Molecular biology, genetics,
biochemistry and genomics have synergized to provide a
large number of potential therapeutic targets that are
entering small-molecule screens for drug discovery. In this
model, biology comes first; chemical tools are developed
primarily to alter the function of biological systems we
already understand. Small molecules are equally capable
of perturbing proteins whose function we don’t under-
stand, however. To identify these molecules we have to
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be willing to look for them, and develop creative ways of
screening for them. Genomic and expression-cloning tech-
nologies promise to make the subsequent step of target
identification much easier. Performing a chemical screen
first, before the biology is understood, may accelerate the
discovery of chemical tools that can help unravel the func-
tion of every protein encoded in an organism’s genome. 
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